Get the Stockscreener App
10.29
0.54%
0.055
Zevra Therapeutics Inc stock is traded at $10.29, with a volume of 193.06K.
It is up +0.54% in the last 24 hours and down -11.72% over the past month.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
See More
Previous Close:
$10.23
Open:
$10.4
24h Volume:
193.06K
Relative Volume:
0.21
Market Cap:
$610.76M
Revenue:
$122.29M
Net Income/Loss:
$122.31M
P/E Ratio:
4.7751
EPS:
2.1539
Net Cash Flow:
$12.00M
1W Performance:
-6.50%
1M Performance:
-11.72%
6M Performance:
-0.34%
1Y Performance:
-12.69%
1-Day Range:
$10.23
$10.60
1-Week Range:
$10.08
$11.46
52-Week Range:
$8.01
$15.04
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(888) 958-1253
Address
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
10.29 | 610.76M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | BTIG Research | Buy |
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October - Investing.com Canada
Zevra Therapeutics president and CEO sells $224,948 in stock - Investing.com
A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane. - Stock Titan
Diluted net income available to common stockholders of Zevra Therapeutics, Inc. – HAN:1GDA - TradingView
Zevra Therapeutics, Inc. Stock (ZVRA)Quote Nasdaq - marketscreener.com
Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets - Investing.com India
ZVRA: Expanding rare disease reach with strong financials, robust IP, and accelerating global growth - TradingView
Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets - Investing.com Canada
Why (ZVRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Zevra Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance
Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium - Quiver Quantitative
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - Barchart.com
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - The Manila Times
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Zevra employees receive stock options that vest over four years - Stock Titan
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - marketscreener.com
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - Yahoo Finance
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
ZVRA Q2 2026 Earnings: EPS Beats Estimates by 27.85% as Bottom-Line Strength ContinuesLow Estimate Range - vinanet.vn
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NEIL F MCFARLANE | Director |
Oct 12 '26 |
Proposed Sale |
11.39 |
20,000 |
227,800 |
0 |
| RAHSAAN THOMPSON | Officer |
Aug 14 '26 |
Proposed Sale |
11.18 |
42,666 |
477,006 |
0 |
| Thompson Rahsaan | Chief Legal & Compliance |
Aug 14 '26 |
Sale |
11.13 |
42,666 |
474,774 |
37,569 |
| Watton Corey Michael | Director |
Aug 10 '26 |
Option Exercise |
4.97 |
12,300 |
61,131 |
14,100 |
| Watton Corey Michael | Director |
Aug 10 '26 |
Sale |
11.25 |
12,300 |
138,377 |
1,800 |
| JOHN BODE | Director |
Jul 08 '26 |
Proposed Sale |
14.85 |
10,516 |
156,163 |
0 |
| Thompson Rahsaan | Chief Legal & Compliance |
Jun 22 '26 |
Sale |
12.68 |
34,557 |
438,304 |
80,235 |
| Rahsaan Thompson | Officer |
May 11 '26 |
Proposed Sale |
11.13 |
36,351 |
404,587 |
0 |
| Thompson Rahsaan | Chief Legal & Compliance |
May 11 '26 |
Sale |
11.30 |
1,794 |
20,272 |
48,125 |
| Bode John B | Director |
Mar 24 '26 |
Option Exercise |
4.93 |
78,400 |
386,512 |
123,400 |
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):